[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-associated-fatty-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-associated-fatty-liver-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,74,98,127,155,188,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100611887","glucagon-resistance-in-patients-with-masld-and-t2dm-100611887",false,"NCT07246421","Glucagon Resistance in Patients With MASLD and T2DM","Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes","Inclusion Criteria:\n\n* BMI \\> 26 kg\u002Fm²\n* confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment\n* steatosis FF% \\> 5,6% on MR spectroscopy for MAFLD group\n\nExclusion Criteria:\n\n* Alcohol abuse (\\>10 units per week for both sexes) or other substance abuse\n* Smoking\n* Current or previous malignant disease\n* Blood donation within the last 3 months prior to the study day\n* Participation in studies involving radioactive isotopes within the past 3 months\n* Pregnancy\n* Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol\u002Fmol)\n* C-peptide \\\u003C 200 pmol\u002FL\n* Previous acute myocardial infarction (AMI)\n* Clinical symptoms of heart failure\n* Current or previous malignant disease\n* Known ongoing systemic disease, except for dyslipidaemia and hypertension\n* Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions:\n\n  1. Participants treated with statins may be included following a 2-week washout period prior to the experimental study day.\n  2. Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only.\n  3. Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day.","ALL","30 Years","70 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\n1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD?\n2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic\u002Fmetabolomic profile in blood and adipose tissue?\n\nResearchers will compare patients with T2DM with and without MASLD to see if the response to basal and high levels of glucagon differs between the groups.\n\nParticipants will attend 2 short visits and 1 full-day visit, including:\n\n* Body scan (DXA) to check fat and bone composition\n* MRI to measure liver fat.\n* Blood tests.\n* Ultrasound to check liver stiffness and scarring.\n* Fat biopsies\n* 8-hour hormone (including glucagon) and tracer infusion\n* PET-CT scans",[27,28],"Metabolic Associated Fatty Liver Disease","Type 2 Diabetes (T2DM)",[30,31,32],"MASLD","Glucagon","Glucagon Resistance","RECRUITING","2026-02-03",{"date":36,"type":37},"2026-02-04","ACTUAL",{"date":39,"type":37},"2026-01-29",{"date":41,"type":21},"2028-07-31",{"name":43,"class":44},"University of Aarhus","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100607236","early-phase-1-efficacy-and-safety-of-rifaximin-in-treating-mafld-100607236","NCT07185932","Efficacy and Safety of Rifaximin in Treating MAFLD","Efficacy and Safety of Rifaximin in Treating Metabolic Associated Fatty Liver Disease: A Pilot Trial","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent;\n2. Aged 18 to 75 years, regardless of gender;\n3. Diagnosed with fatty liver disease within the past 6 months;\n4. Presence of at least one of the following metabolic abnormalities:\n\n(1) Overweight or obesity (BMI ≥23 kg\u002Fm²) (2) Type 2 diabetes (T2DM) (3) Clinical evidence of metabolic dysfunction (defined as meeting at least two of the following criteria): A. Waist circumference ≥90 cm for males or ≥80 cm for females B. Blood pressure ≥130\u002F85 mmHg and\u002For diagnosed hypertension under treatment C. Fasting plasma triglycerides ≥1.7 mmol\u002FL (150 mg\u002FdL) or diagnosed hypertriglyceridemia under treatment D. Fasting HDL-C \\\u003C1.0 mmol\u002FL (40 mg\u002FdL) for males or \\\u003C1.3 mmol\u002FL (50 mg\u002FdL) for females, or diagnosed dyslipidemia under treatment E. Prediabetes: fasting glucose 5.6-6.9 mmol\u002FL (100-125 mg\u002FdL) or 2-hour postprandial glucose 7.8-11.0 mmol\u002FL (140-199 mg\u002FdL) or HbA1c 5.7%-6.4% (39-47 mmol\u002Fmol) F. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score ≥2.5 G. Plasma high-sensitivity C-reactive protein (hs-CRP) \\>2 mg\u002FL 5. Liver fat content ≥8% as measured by MRI proton density fat fraction (MRI-PDFF).\n\nExclusion Criteria\n\n1. Cirrhosis - Confirmed by clinical, laboratory, imaging, and\u002For liver biopsy.\n2. Chronic liver disease of other etiologies (e.g., viral\u002Fautoimmune hepatitis, alcoholic liver disease, drug-induced liver injury)\n3. Secondary hepatic steatosis (e.g., drug-induced, total parenteral nutrition-related, or hypothyroidism-associated);\n4. Recent use of intestinal flora-modifying agents, or unstable regimens of medications (including hepatoprotectants, metformin, thiazolidinediones, fibrates, statins, et al) within 4 weeks prior to enrollment;\n5. Agents with potential effects on MAFLD progression administered within 12 weeks prior to enrollment, excluding those maintained at stable doses for ≥24 weeks (e.g., Glucagon-like peptide-1 receptor agonists, Dipeptidyl peptidase IV inhibitors, Obeticholic acid, Sodium-glucose cotransporter 2 inhibitors, Resmetirom or anti-obesity medications)\n6. Poorly controlled diabetes (HbA1c \\>9%)\n7. Jaundice (total bilirubin ≥85 μmol\u002FL), or Renal dysfunction (serum creatinine ≥1.2 × ULN)\n8. History of bariatric surgery\n9. Active or suspected malignancy\n10. Severe systemic conditions - Including: Inflammatory diseases (e.g., connective tissue disorders), Biliary\u002Fpancreatic disorders, Chronic\u002Facute infections, Severe cardiovascular, pulmonary, or hematologic diseases, Myocardial infarction or stroke within 6 months, Psychiatric disorders\n11. HIV infection\n12. Known hypersensitivity to rifaximin\n13. MRI contraindications - Including: Metal implants, Claustrophobia, Body size exceeding scanner capacity\n14. Pregnancy, lactation, or planned pregnancy\n15. Participation in another drug trial within 3 months\n16. Other conditions deemed unsuitable by investigators","18 Years","75 Years",{"count":56,"type":21},40,[58],"EARLY_PHASE1","Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.\n\nTarget Population: patients diagnosed with MAFLD. Intervention: this single-center, single-arm exploratory study will enroll up to 40 eligible MAFLD patients who meet the inclusion criteria, do not meet any exclusion criteria, and provide written informed consent. Participants will receive oral rifaximin at a dosage of 1200 mg\u002Fday (400 mg, three times daily) for 24 weeks. Patients will be advised to maintain their usual physical activity and adhere to a recommended dietary plan (e.g., Mediterranean diet). Concurrent therapies such as hepatoprotective agents, lipid-lowering medications, and antihypertensive treatments will remain unchanged, with close monitoring of relevant parameters. No additional prescription or over-the-counter drugs that may affect fatty liver progression or alter gut microbiota composition will be permitted during the study.\n\nThe primary endpoint will be assessed at 24 weeks. If liver proton density fat fraction (PDFF) remains ≥ 8% after 24 weeks of rifaximin therapy, treatment will be extended for an additional 12 weeks, followed by reevaluation of PDFF changes. The maximum total treatment duration will not exceed 48 weeks. All patients will undergo a 24-week post-treatment follow-up period after discontinuation of rifaximin.\n\nInvestigational Drug: Rifaximin (Alfa Wassermann S.p.A., Italy).",[61],"Metabolic-associated Fatty Liver Disease",[63,64],"metabolic-associated fatty liver disease","Rifaximin","2025-09-12",{"date":67,"type":37},"2025-09-22",{"date":69,"type":37},"2024-08-10",{"date":71,"type":21},"2027-12-31",{"name":73,"class":44},"Shanghai Changzheng Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100604442","to-explore-the-value-of-new-mr-technology-in-non-invasive-quantitative-assessment-of-systemic-metabolism-disease-status-and-prognosis-in-patients-with-metabolic-associated-fatty-liver-disease-100604442","NCT07149571","To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease","Inclusion Criteria:\n\n1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;\n2. Age\u002Fgender: unlimited;\n3. Patients who voluntarily participate in clinical trials and sign written subject informed consent\n\nExclusion Criteria:\n\n1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;\n2. Voluntarily participation in the study and provision of written informed consent.",true,{"count":82,"type":21},500,"OBSERVATIONAL","The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease",[86,61],"Nonalcoholic Fatty Liver Disease",[88],"MRI, metabolism-related fatty liver disease","2025-08-29",{"date":91,"type":37},"2025-09-02",{"date":93,"type":37},"2025-04-01",{"date":95,"type":21},"2032-12-31",{"name":97,"class":44},"Tongji Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":106,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100602376","evaluation-of-non-invasive-tests-for-metabolic-liver-disease-100602376","NCT07122700","Evaluation of Non-Invasive Tests for Metabolic Liver Disease","Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study","NIMBLE","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged \\> 18 years and \\\u003C 75 years\n4. Participants must exhibit some manifestations of metabolic dysregulation. Either:\n\nA. Physician-diagnosed T2DM for at least 90 days with HbA1c \\> 6.5 and antidiabetic therapy, if any, stable for at least 90 days prior to screening or B. At least any one of the following six metabolic syndrome criteria \\[6\\]\n\n1\\. body mass index (BMI) of \\> 25 kg\u002Fm2 2. waist circumference: i. \\> 102 cm for men ii. \\> 88.9 cm for women 3. fasting triglyceride concentration \\> 150 mg\u002FdL i. or ongoing treatment with triglyceride lowering medication 4. HDL-cholesterol concentration: i. \\\u003C 40 mg\u002FdL for men ii. \\\u003C 50 mg\u002FdL for women iii. or ongoing treatment with cholesterol lowering medication. 5. fasting glucose concentration \\> 100 mg\u002FdL 6. either semi-recumbent or supine blood pressure systolic \\> 130 mmHg and\u002F or diastolic \\> 85 mmHg i. or ongoing treatment with antihypertensive medication. 5. FIB-4 \\> 1.3 (age \\\u003C 65 years) and \\> 2.0 (age \\> 65 years) 6. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration\n\nExclusion Criteria:\n\n1. Known history or evidence of other forms of chronic liver disease other than MASLD\u002FMASH including but not limited to viral hepatitis B or C, autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, drug-induced liver disease, conditions involving bile duct obstructions, liver cancer, past history of HCC or HCC treatment, listed for or history of liver transplantation, prior resection of liver, etc.\n2. Current or past evidence of decompensated liver disease defined by overt ascites that is clinically obvious and requires diuretic therapy, overt encephalopathy requiring therapy or history of variceal hemorrhage\n3. Circulating Alanine aminotransferase (ALT)\\> 5xULN\n4. Ongoing or recent (within the last two years prior to screening) consumption of significantly greater than moderate amounts of alcohol.\n\n   * A standard alcoholic drink is any drink that contains about 14 g of pure alcohol, such as 12 fluid ounces of regular beer 8-10 fluid ounces of malt liquor or flavored malt beverages such as hard seltzer 5 fluid ounces of table wine 3-4 fluid ounces of fortified wine such as sherry or port 2-3 fluid ounces of cordial liqueur or aperitif 1.5 fluid ounces (a single jigger or shot) of brandy, cognac, or distilled spirits such as gin, rum, tequila, vodka, whiskey, etc.\n   * Significantly greater than moderate alcohol consumption is defined as on average over a 2-year period prior to screening:\n\n   Women\n   * \\>1 standard drink per day and\u002For\n   * \\>14 standard drinks per week Men\n   * \\>2 standard drinks per day and\u002For\n   * \\>21 standard drinks per week in men\n\n     * An Alcohol Use Disorders Identification Test (AUDIT) score of 7 or higher\n     * A PEth test score of ≥ 20ng\u002Fml.\n5. In the opinion of the investigator, any contraindications to liver biopsy including but not limited to having significant uncorrected coagulopathy or thrombocytopenia, on chronic anticoagulation with Direct Oral Anticoagulants (DOACs), or on low dose heparin or Warfarin.\n6. Uncontrolled systolic blood pressure \\> 180 mmHg and diastolic blood pressure \\> 120 mmHg at screening. Blood pressure will be obtained after at least 10 minutes of resting in a semi-recumbent or supine position.\n7. Any systemic disease that in the opinion of the investigator precludes inclusion of the patient in the trial\n8. Unable or unwilling to provide informed consent\n9. Unwilling to undergo liver biopsy procedure\n10. Unable or unwilling to comply with requirements for study procedures (such as fasting)\n11. Unable to perform study procedures in the opinion of the investigator\n12. Participants who are unwilling or unable (e.g. due active implants such as pacemaker or having a waist diameter (calculated as: diameter = circumference \u002F π) 70cm, unless a wide-bore MRI machine is available) to undergo MRI procedures.\n13. Pregnancy or planned pregnancy within 4 months of screening.\n14. Participation in another clinical trial within 30 days, or dosing with an investigational agent within 90 days prior to signing the ICF for this study.",{"count":107,"type":21},400,"The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.",[27,110,111,112,113,114,115,116],"Metabolic Associated Steatotic Liver Disease","Cirrhosis, Liver","NASH","Liver Fibrosis","Liver Fat","Liver Steatoses","Liver Inflammation","2025-08-07",{"date":119,"type":37},"2025-08-14",{"date":121,"type":37},"2025-05-13",{"date":123,"type":21},"2026-07-31",{"name":125,"class":44},"Foundation for the National Institutes of Health",4,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100583995","effect-of-low-valine-diet-on-body-weight-and-metabolic-parameters-100583995","NCT06883578","Effect of Low Valine Diet on Body Weight and Metabolic Parameters","Inclusion Criteria:\n\n* Male or female, 16 years old ≤ age ≤ 80 years old;\n* BMI ≥ 24kg\u002Fm2\n\nExclusion Criteria:\n\n* Excessive drinkers (defined as: in the past 6 months, the weekly alcohol intake of men exceeds 140g, and that of women exceeds 70g);\n* Liver diseases caused by other reasons: such as alcoholic liver disease, acute and chronic viral hepatitis, drug-induced, immune hepatitis (AMA, SMA, ANA), cirrhosis, liver cancer, etc.;\n* Other diseases that affect glucose and lipid metabolism: hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.;\n* Poorly controlled diabetic patients: HbA1c \\>9.5% within three months; or use of hypoglycemic drugs that may affect weight, including pioglitazone, GLP-1, SGLT2 inhibitors;\n* Chronic kidney disease or severe renal impairment, defined as serum creatinine greater than 2.0mg\u002FdL;\n* Serum ALT greater than 3 times the upper limit of normal;\n* Life expectancy of no more than 3 years in the presence of serious health conditions;\n* Those who plan to get pregnant in the near future;\n* Those who cannot participate in the follow-up of the intervention due to other conditions;\n* Continuously used drugs that may cause weight changes for more than 2 weeks in the past year (such as glucocorticoids, thyroid hormones, etc.);\n* Participated in other clinical trials in the past 4 weeks;\n* Those who had gastric volume reduction surgery or digestive tract surgery;\n* Those diagnosed with any tumor disease;\n* Subjects who participated in strenuous exercise or planned to change their diet structure;\n* Unable to sign the informed consent form.","16 Years","80 Years",{"count":136,"type":21},48,[24],"This study aimed to explore the effects of ordinary meal replacements and low-valine meal replacements on the weight and risk of related metabolic diseases in overweight\u002Fobese patients through a randomized double-blind controlled clinical trial.",[140,27,141],"Overweight\u002Fobesity","Metabolic Diseases",[143,144,145],"Obesity","Dietary intervention","Low valine meal replacement","2025-03-15",{"date":148,"type":37},"2025-03-19",{"date":150,"type":37},"2025-02-18",{"date":152,"type":21},"2026-04-30",{"name":154,"class":44},"Shanghai Zhongshan Hospital",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100574805","characterization-and-management-of-metabolic-dysfunction-associated-fatty-liver-disease-mafld-100574805","NCT06764056","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.","METAfoie","Inclusion Criteria:\n\n* Body mass index between 30 and 50 kg\u002Fm2;\n* Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.\n\nExclusion Criteria:\n\n* Type 1 diabetes diagnosis;\n* Alcohol consumption exceeding recommendations \\[\\>140 g\u002Fweek (women) and \\>210 g\u002Fweek (men)\\];\n* Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.);\n* Pharmacological treatment targeting obesity active or ended in the last 3 months;\n* Bariatric surgery;\n* Gastro-intestinal pathologies (GI cancers, IBD, etc.);\n* Capsulated probiotics consumption;\n* Antibiotic treatment in the last 3 months;\n* Pregnancy;\n* Cirrhosis diagnosis (hepatic decompensation).",{"count":164,"type":21},120,[24],"The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:\n\nDoes an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity?\n\nParticipants will either participate in one of three groups:\n\n* Nutrition: Participant will only have a regular follow-up with a registered dietician;\n* Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician;\n* Semaglutide: Participants will start a new medication targeting obesity.",[27,168,143],"Metabolic Associated-dysfunction Steatohepatitis (MASH)",[143,170,171,172,173,174,175,176,177],"Metabolic associated fatty liver disease","GLP-1 receptor analogs","Pharmacotherapy","Nutrition","Transient elastography","Semaglutide","Microbiome","Lipidomics","NOT_YET_RECRUITING","2025-01-07",{"date":181,"type":37},"2025-01-08",{"date":183,"type":21},"2025-01",{"date":185,"type":21},"2026-05",{"name":187,"class":44},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":45},"100485179","prevalence-of-mafld-in-patients-with-type-2-diabetes-in-jiangsu-province-of-china-100485179","NCT05597709","Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes\n* UAP were measured based on iLivTouch\n* Willing to attend this study and able to provide the written informed consent.\n\nExclusion Criteria:\n\n* Other types of diabetes\n* Patients unable to receive regular follow-up",{"count":196,"type":21},2900,"In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.",[199,27],"Type 2 Diabetes Mellitus in Remission",[201,170,202],"Type 2 diabetes mellitus","ultrasound attenuation parameter","2022-10-24",{"date":205,"type":37},"2022-10-28",{"date":207,"type":37},"2022-07-01",{"date":209,"type":21},"2027-06-01",{"name":211,"class":212},"Wuxi Hisky Medical Technology Co Ltd","INDUSTRY",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":134,"enrollmentInfo":219,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":45},"100406504","a-prospective-cohort-study-of-metabolic-associated-fatty-liver-disease-in-china-100406504","NCT04573283","A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China","Inclusion Criteria:\n\n* Diagnosed as hepatic steatosis in adults (fulfill at least one of the followings):\n\n  1. Liver ultrasound shows liver parenchymal hyperechoic or \"bright liver\"\n  2. Controlled attenuation-parameter (CAP) ≥248dB\u002Fm\n  3. Hepatic steatosis diagnosed by CT\u002FMRI\u002FMRS\n  4. MRI-based proton-density fat fraction (MRI-PDFF) shows liver fat content\\>8%\n  5. Fatty liver confirmed by liver histology.\n\nExclusion Criteria:\n\n1. Diagnosed with hepatocellular carcinoma or other malignancy (in accordance with the appropriate diagnostic criteria);\n2. During pregnancy;\n3. Patients with history of liver transplantation;\n4. Patients with serious cardiovascular and cerebrovascular events (such as acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.).",{"count":220,"type":21},3000,"Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new concept proposed in 2020. Unlike non-alcoholic fatter liver disease (NAFLD), the diagnosis of MAFLD requires the presence any of the following 3 metabolic risks, including overweight\u002Fobesity, presence of diabetes mellitus, and evidence of metabolic dysregulation. However, there are patients that have hepatic steatosis but no metabolic risk, who thus do not meet the diagnostic criteria of MAFLD. Besides, there are patients with both MAFLD and other liver diseases. The clinical features and the management of these patients remain unclear. Thus, further histopathological and clinical study is required to elucidate and compare the characteristics of MAFLD and NAFLD.\n\nHere, in this single-center, prospective clinical study, investigators are planning to establish a long-term follow-up cohort of patients with either MAFLD or NAFLD. In order to understand the risk of developing liver-related complications and important extra-hepatic outcomes (e.g. cardiovascular disease), and also to better elucidate the risk of disease progression in \"lean\" NAFLD individuals without any metabolic dysregulation and MAFLD individuals with dual or multiple causes.\n\nUltimately, investigators aim to improve the diagnosis of MAFLD and improve patients' outcomes.",[27],[224,225,226,227],"metabolic associated fatty liver disease","metabolic","nonalcoholic fatty liver disease (NAFLD)","non-MR-NAFLD","2021-02-04",{"date":230,"type":37},"2021-02-09",{"date":232,"type":37},"2020-08-17",{"date":234,"type":21},"2030-08-17",{"name":236,"class":44},"Nanfang Hospital, Southern Medical University"]